Haloperidol genetic polymorphism

Sparteine has been used as a marker of the metabohc activity of CYP2D6 (1). Pharmacokinetic studies have shown that its metabolic oxidation exhibits genetic polymorphism and that about 6-9% of the Caucasian population are poor metabohzers. Quinidine, haloperidol, and moclobemide are all potent inhibitors of the oxidative metabohsm of sparteine (2). 

Park J-Y, Shon J-H, Kim K-A, Jung H-J, Shim J-C, Yoon Y-R, Cha I-J, Shin J-G. Combined effects of itraconazole and CYP2D6 10 genetic polymorphism on the pharmacokinetics and pharmacocfynamics of haloperidol in healtiiy subjects. J Clin Psychopharmacol (2006) 26, 135-42. 

---